image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 9 days, don't miss out!

SigmaRoc

March 2024

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • SRC
  • Price:
  • 64.5p
A well-timed write-up last month with the shares rising after Sigmaroc said thanks to an excellent final quarter, it expects to report underlying FY23 EBITDA and eps ahead of expectations. Revenues are expected to be 8% higher year-on-year at c. £580m with all newly acquired businesses performing ahead of expectations. Like-for-like revenue grew 2% despite a 4% reduction in volumes, “reflecting the group’s diversified geographic end-market profile”. One highlight was the 1.1% improvement in EBITDA margins to 20% helped by cost savings of £4m while eps is expected to be greater than 8p, above the prior year despite a significant increase in finance costs and after absorbing the cash raise dilution in February 2023. Within it ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author